Nothing new in here, unfortunately, and biopharma VCs like @LifeSciVC continuing to push to offshore biotechnology without a care for strategic implications for US. It's not 2008 anymore -- we're simply in a different strategic relationship between the US and China now.
From the post:
"The reality is rank and file talent is less expensive in China. Why wouldn’t we want to augment our global workforces with some of these resources? Why would we want to be less efficient?"
Low cost scientific labor and more lax regulation around clinical trials are the two big drivers for the rapid offshoring a very strategic technology. We are now at 1/3 empty lab space in Boston area and R&D jobs declined by 1,100 in 2025 -- the first declines since @MassBio started tracking it. I'm disappointed that our leaders aren't stepping up to protect and invest in our US biotechnology R&D ecosystem that did so much for them. Doing the opposite in fact -- it's tiring.
We have the power to keep this strategic industry onshore -- it's much easier to keep it then to lose it and try to bring it back. Our power originates in the fact that US citizens are the source of 70% of the profits in the drug industry. We set the rules on what drugs can be sold, how USG reimburses for drugs, etc.
We should add biotechnology to the COINS Act list of strategic technologies! And lean in to be make our US R&D infrastructure and trials more efficient! We can do both! Let's get to work! I'd love you to help us Bruce!
@mbeisen Aaron Klug’s 1968 defense of RF is dispositive: “as she later told me—Franklin did not appreciate the significance of the fact that the space group of the A form was C2…the DNA molecules must therefore possess perpendicular dyads…only Crick seems to have appreciated this fact”